REG-Shire Limited: Director/PDMR Shareholding

.
Director/PDMR Shareholding

Basingstoke, UK and Philadelphia, US - June 19, 2008 - Shire Limited (LSE: SHP,
NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that
on June 18, 2008, upon Mr Angus Russell becoming the Chief Executive Officer of
the Company, the following awards under the Shire Portfolio Share Plan (the
"Plan") were granted to Mr Russell. The awards will bring Mr Russell's long
term incentive awards in line with the stated policy for the Chief Executive
Officer disclosed in the Company's Remuneration Report.

A consistent methodology has been used to calculate the number of shares
subject to this award, in line with all awards granted previously to Persons
Discharging Managerial Responsibilities under the Plan (i.e. using the average
share price in the previous financial year which, in 2007, was �11.55).

Awards of Stock Settled Appreciation Rights ("SARs") under Part A of the Plan

Type of Security No. of Ordinary Shares Exercise Price

Ordinary Share 123,547 �8.13

SARs will normally vest after three years, subject to performance targets being
satisfied. Once vested, SARs will be capable of exercise for a period of two
years. No consideration was paid for the grant of the SARs.

Performance Share Awards ("PSP Awards") under Part B of the Plan

Type of Security No. of Ordinary Shares Market value

Ordinary Share 96,410 �8.13

The PSP awards will normally vest after three years, subject to performance
targets being satisfied. No consideration was paid for the grant of PSP awards.

Following this transaction, Mr. Russell holds options over 554,760 Ordinary
Shares (of which options over 552,418 Ordinary Shares have vested) and awards
over 881,580 Ordinary Shares (of which all are still to vest).

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
of the Disclosure Rules and Transparency Rules.

T May

Company Secretary

For further information please contact:

Investor Relations Cl�a Rosenfeld (Rest of the World) +44 1256 894 160

Eric Rojas (North America) +1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit and hyperactivity disorder (ADHD),
human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The
structure is sufficiently flexible to allow Shire to target new therapeutic
areas to the extent opportunities arise through acquisitions. Shire's
in-licensing, merger and acquisition efforts are focused on products in niche
markets with strong intellectual property protection either in the US or
Europe. Shire believes that a carefully selected portfolio of products with
strategically aligned and relatively small-scale sales forces will deliver
strong results.

For further information on Shire, please visit the Company's website:
www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com

Press Release

END
nPRrJE681a